Share
198 Posts.
lightbulb Created with Sketch. 8
clock Created with Sketch. 19/12/20
13:18
Share
Originally posted by Irbox:
↑
Ok here are my thoughts.. another horrible day to be an investor and believer in MSB, however, I believe the share price does not currently reflect the company or their cells, not even close. There has yet to be a study which says the cells don’t work. There was overwhelming evidence that Ryoncil saves children’s lives with acute GVHD and this was reflected in the almost unanimous 9-1 ODAC support. The only reason this product wasn’t approved was due to a single arm study. I have no doubt that FDA will grant approval once a secondary study is verified in adult aGVHD. Once commercialisation occurs MSB is guaranteed revenue and revenue is the single most important thing when it comes to a share price.
Expand
Thanks for your analysis. It has given warm comfort to believe in MSB. Although, I don't think that I could still believe that SI is reliable when he mentioned the encouraging data of the upcoming ulcerative colitis and Crohn's disease.
(20min delay)